[go: up one dir, main page]

MX2009012969A - Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos. - Google Patents

Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.

Info

Publication number
MX2009012969A
MX2009012969A MX2009012969A MX2009012969A MX2009012969A MX 2009012969 A MX2009012969 A MX 2009012969A MX 2009012969 A MX2009012969 A MX 2009012969A MX 2009012969 A MX2009012969 A MX 2009012969A MX 2009012969 A MX2009012969 A MX 2009012969A
Authority
MX
Mexico
Prior art keywords
treatment
therapeutic agent
unacylated ghrelin
metabolic disorders
polypeptide
Prior art date
Application number
MX2009012969A
Other languages
English (en)
Inventor
Ezio Ghigo
Aart Jan Van Der Lely
Riccarda Granata
Original Assignee
Alize Pharma Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alize Pharma Sas filed Critical Alize Pharma Sas
Publication of MX2009012969A publication Critical patent/MX2009012969A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Prostheses (AREA)

Abstract

Un polip?ptido aislado comprendiendo cualquier fragmento de amino?cido de grelina no acilada o cualquier an?logo de la misma, en donde el polip?ptido tiene una actividad seleccionada del grupo que consiste de a) disminuir los niveles de glucosa en sangre; b) aumentar la secreci?n y/o sensibilidad de insulina; c) unir a c?lulas secretoras de insulina; y d) promover la supervivencia de c?lulas secretoras de insulina. As? como el uso del polip?ptido en el tratamiento de un desorden asociado con metabolismo de glucosa deteriorado.
MX2009012969A 2007-05-31 2008-05-30 Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos. MX2009012969A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94118607P 2007-05-31 2007-05-31
PCT/EP2008/056727 WO2008145749A1 (en) 2007-05-31 2008-05-30 Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders

Publications (1)

Publication Number Publication Date
MX2009012969A true MX2009012969A (es) 2010-04-27

Family

ID=39677677

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009012969A MX2009012969A (es) 2007-05-31 2008-05-30 Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.

Country Status (10)

Country Link
US (2) US20100168033A1 (es)
EP (1) EP2152297B1 (es)
JP (1) JP5485876B2 (es)
CN (1) CN101678084B (es)
AU (1) AU2008257448B9 (es)
CA (1) CA2686803C (es)
DK (1) DK2152297T3 (es)
ES (1) ES2538111T3 (es)
MX (1) MX2009012969A (es)
WO (1) WO2008145749A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
US8318664B2 (en) 2007-05-31 2012-11-27 Alize Pharma Sas Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity
US20100168033A1 (en) 2007-05-31 2010-07-01 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
US8476408B2 (en) * 2008-06-13 2013-07-02 Alize Pharma Sas Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease
CA2779088A1 (en) 2009-11-16 2011-05-19 Mellitech [1,5]-diazocin derivatives
TR201900438T4 (tr) 2011-12-15 2019-02-21 Millendo Therapeutics Sas Prader-wıllı sendromunun tedavisinde kullanıma yönelik asillenmemiş girelin fragmentleri.
KR20220051197A (ko) 2012-05-17 2022-04-26 익스텐드 바이오사이언시즈, 인크. 개선된 약물 전달용 캐리어
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014141124A1 (en) * 2013-03-13 2014-09-18 Institut National De La Sante Et De La Recherche Medicale Erk-pathway activating compound for preventing or treating leptin resistance
WO2014203074A2 (en) * 2013-06-21 2014-12-24 Alize Pharma Sas Use of unacylated ghrelin, fragments and analogs thereof as antioxidant
CA2964463C (en) 2014-10-22 2024-02-13 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
US9616109B2 (en) 2014-10-22 2017-04-11 Extend Biosciences, Inc. Insulin vitamin D conjugates
US12311011B2 (en) 2018-09-04 2025-05-27 Cornell University Des-acyl ghrelin and analogs as cancer therapies
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) * 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) * 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US6271198B1 (en) * 1996-11-06 2001-08-07 Genentech, Inc. Constrained helical peptides and methods of making same
US6627729B1 (en) * 1997-03-24 2003-09-30 Zymogenetics, Inc. TML peptides
AU2001228325A1 (en) 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
AU2001259056A1 (en) 2000-05-17 2001-11-26 Eli Lilly And Company Method for selectively inhibiting ghrelin action
WO2001092292A2 (en) 2000-05-30 2001-12-06 Merck & Co., Inc. Ghrelin analogs
JP4493913B2 (ja) 2001-01-31 2010-06-30 中外製薬株式会社 低栄養症状疾患治療剤
US6872548B2 (en) * 2001-01-31 2005-03-29 Human Genome Sciences, Inc. Scaffolded fusion polypeptides and compositions and methods for making the same
US7666833B2 (en) 2001-12-18 2010-02-23 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
CA2470235C (en) 2001-12-18 2012-02-07 Theratechnologies Inc. Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof
EP1455814B1 (en) 2001-12-18 2012-04-04 Alizé Pharma SAS Pharmaceutical compositions comprising unacylated ghrelin for use in the treatment of insulin resistance
AU2003235401B2 (en) 2002-05-21 2008-09-25 Daiichi Sankyo Company, Limited Medicinal compositions containing ghrelin
WO2005039624A1 (en) 2003-10-24 2005-05-06 Theratechnologies Inc. Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions
WO2006045319A2 (en) 2004-10-27 2006-05-04 Gastrotech Pharma A/S Uses of growth hormone secretagogues in the treatment of individuals suffering from renal and/or liver failure
US7290883B2 (en) 2005-03-24 2007-11-06 Tte Tchnology, Inc. System and method for projecting video onto a screen
US8653022B2 (en) 2006-03-28 2014-02-18 Liat Mintz Use of ghrelin splice variant for treating hypercholesterolemia and/or high cholesterol and/or high cholesterol complication and/or lipemia and/or lipemia complication and/or coronary heart disease and/or weight management and/or diabetes and/or hyperglycemia
US20100168033A1 (en) 2007-05-31 2010-07-01 Alize Pharma Sas Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders
EP2067481A1 (en) 2007-12-03 2009-06-10 Charité-Universitätsmedizin Berlin Therapeutic use of desacyl ghrelin

Also Published As

Publication number Publication date
WO2008145749A1 (en) 2008-12-04
CA2686803A1 (en) 2008-12-04
AU2008257448B2 (en) 2013-02-21
AU2008257448B9 (en) 2013-07-11
ES2538111T3 (es) 2015-06-17
EP2152297B1 (en) 2015-04-29
DK2152297T3 (en) 2015-06-01
CN101678084B (zh) 2015-01-21
JP5485876B2 (ja) 2014-05-07
EP2152297A1 (en) 2010-02-17
US20080312133A1 (en) 2008-12-18
CN101678084A (zh) 2010-03-24
US20100168033A1 (en) 2010-07-01
CA2686803C (en) 2016-05-03
JP2010528092A (ja) 2010-08-19
US8222217B2 (en) 2012-07-17
AU2008257448A1 (en) 2008-12-04

Similar Documents

Publication Publication Date Title
MX2009012969A (es) Grelina no acilada como agente terapeutico en el tratamiento de trastornos metabolicos.
WO2009017655A3 (en) Methods and compositions for stimulating the proliferation or differentiation of stem cells with substance p or an analog thereof
EA201170149A1 (ru) Новые аналоги инсулина пролонгированной активности
SG158112A1 (en) Hepatocyte growth factor (hgf) binding proteins
MX2008013304A (es) Compuestos de peptido 1 tipo glucagon.
MX343360B (es) Conjugados peptidicos de agonistas del receptor de glp-1 y gastrina y su uso.
WO2007143098A3 (en) Hepatocyte growth factor (hgf) binding proteins
MX2020009811A (es) Tratamiento de la diabetes en pacientes con control glucemico insuficiente a pesar de la terapia con un farmaco oral o no oral antidiabetico.
MX2009011359A (es) Derivados de pirimidinona y sus metodos de uso.
MY170728A (en) Treatment for diabetes in patients inappropriate for metformin therapy
DK2195013T3 (da) Terapeutisk anvendelse af en vækstfaktor, METRNL
MX2009011357A (es) Derivados de tetrahidropirido[4,3-d] pirimidinona y metodos de uso de los mismos.
EA201101187A1 (ru) Антидиабетические лекарственные средства, содержащие ингибитор dpp-4 (линаглиптин) необязательно в комбинации с другими антидиабетическими средствами
MX356873B (es) Uso farmacéutico de una esfingomielinasa ácida (asm) con aumento escalonada de la dosis para tratar la deficiencia de esfingomielinasa ácida.
MX2011007397A (es) Inhibidores de dpp-iv para el tratamiento de la diabetes en pacientes pediatricos.
SG10201906478VA (en) Human antibodies to the glucagon receptor
MX2019005130A (es) Inhibidores de dpp-iv, tales como la linagliptina, y composiciones farmaceuticas o combinaciones que comprenden los mismos, para usarse en el tratamiento de pacientes diabeticos tipificados geneticamente.
MX2007010560A (es) Roflumilast para el tratamiento de diabetes mellitus.
WO2008027420A3 (en) Implantable devices for producing insulin
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
WO2008147483A8 (en) Neurogenic compounds
LT2013018A (lt) Farmacinė kompozicija, skirta gydyti diabetą ir metabolinius sutrikimus
WO2009135165A3 (en) Small humanin-like peptides
WO2005113016A3 (en) Modulation of glucose-6-phosphatase translocase expression
IL191365A0 (en) A preparation for use in the case of diseases of the metabolism of blood, including diabetes

Legal Events

Date Code Title Description
FG Grant or registration